Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Cannabinoid receptor 2 a target for osteoporosis

May 29, 2006

Agents for metabolic disorders disclosed

May 26, 2006

FDA gives 510(k) clearance for SynVitro Cumulase

May 26, 2006

Paricalcitol improves bone strength in renal bone disease model

May 26, 2006

SB-462795 increases bone strength in male monkeys

May 25, 2006

Teriparatide studied in new trial for osteogenesis imperfecta

May 25, 2006

Enrollment slower than expected in Proellex studies

May 24, 2006

Repros updates progress of Androxal study

May 24, 2006

Recent patents describe new treatment options for endocrine-related disorders

May 23, 2006

Phase II study begins for MK-0354 in patients with dyslipidemia

May 23, 2006

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 18, 2026.
ASGCT 2026: Directed evolution in gene therapy
BioWorld
Directed evolution has become a central pillar in gene therapy. This engineering strategy enables the generation of more efficient variants of genetic editors and...
Fosun secures rights to Aribio’s AR-1001 in potential $4.7B deal
BioWorld
Shanghai Fosun Pharmaceutical (Group) Co. Ltd. is paying $60 million up front for an option to secure exclusive rights to Aribio Co. Ltd.’s oral phase III-stage...
Biogen AD drug shows tau, cognition benefit, despite trial miss
BioWorld
Biogen Inc. has decided to advance diranersen (BIIB-080) into registrational trials for early Alzheimer’s disease, even though the antisense oligonucleotide...
NTX-819, a novel mGlu7 NAM for psychiatric disorders
BioWorld Science
Increasing evidence supports metabotropic glutamate mGlu7 receptor as a promising target in psychiatric disorders. Neurosterix Pharma Sarl has presented data on...